IMAC Holdings presents at the autumn harvest - Best ideas from the buyers' side on October 5, 2021 |  Your money

BRENTWOOD, Tenn, Sept. 28, 2021 (GLOBE NEWSWIRE) – IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or the “Company”), a provider of innovative medical advances and care, specializes in orthopedic treatments for regenerative rehabilitation without the use of surgery or opioids, was invited to present at the Autumn Harvest – Best Ideas from the Buy-Side Conference, which will take place virtually from October 5, 2021.

IMAC CEO Jeff Ervin is expected to give a presentation on Tuesday, October 5th at 11:30 am ET. The management is available for one-on-one calls throughout the conference. Investors can register here. To receive additional information, to request an invitation or to arrange a one-on-one interview, please send an email to [email protected]

About the autumn harvest – best ideas from the buy-side conference

The Fall Harvest – MicroCap Rodeo is back with its fourth “Best Ideas” conference. This conference is a virtual conference that brings you the 35 best buy-side ideas. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas know that we’re focused on Alpha.

About IMAC Holdings, Inc.

IMAC Holdings owns and manages health and wellness centers that provide sports medicine, orthopedic, and life science therapies for motion-impairing diseases. IMAC consists of three divisions: Outpatient Medical Centers, BACKSPACE and a Clinical Research Department. Providing treatments for the aging population, IMAC Holdings owns or manages more than 15 outpatient medical clinics and has partnered with several active and former professional athletes, including Ozzie Smith, David Price, Mike Ditka and Tony Delk, to promote a minimally invasive approach to sports medicine . IMAC’s BACKSPACE Spinal Health and Wellness Retail Centers provide chiropractic treatment within Walmart locations. IMAC’s research division is currently conducting a Phase I clinical trial evaluating a mesenchymal stem cell therapy candidate for bradykinesia due to Parkinson’s disease. More information is available at


IMAC press contact: Laura Fristoe [email protected]

Investor Relations:

Bret Shapiro (516) 222-2560 [email protected]

SOURCE: IMAC Holdings, Inc. (Nasdaq: IMAC)

Ford is adding 10,800 jobs in the manufacture of electric vehicles and batteries

Copyright 2021 GlobeNewswire, Inc.